Atrophic Vaginitis (Vaginal Atrophy) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Atrophic Vaginitis (Vaginal Atrophy) Market Outlook

Thelansis’s “Atrophic Vaginitis (Vaginal Atrophy) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Atrophic Vaginitis (Vaginal Atrophy) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Atrophic Vaginitis (Vaginal Atrophy) Overview

Atrophic vaginitis is an inflammatory condition associated with vaginal atrophy caused by reduced estrogen levels, mainly occurring during menopause. Vaginal atrophy leads to thinning of the vaginal epithelium, decreased vaginal rugae and elasticity, and reduced vaginal secretions. It affects pre-menopausal women and up to 50% of post-menopausal women. The hypoestrogenic state responsible for atrophic vaginitis can result from natural menopause or be induced by medical interventions like surgery, radiation, chemotherapy, or certain medications such as Selective estrogen receptor modulators, Selective estrogen receptor degraders, and antigonadotropins. Lower estrogen levels cause alterations in the vaginal environment, disrupting the normal flora, leading to an overgrowth of skin and rectal pathogens due to decreased Lactobacillus spp. The diagnosis of atrophic vaginitis is typically based on the patient's history and specific physical examination findings. Symptoms include vaginal dryness, burning, pruritis, abnormal vaginal discharge, and painful intercourse. External genitalia signs may include atrophy of the labia majora and minora, dry labia, vulvar dermatoses, vulvar lesions, or sparse pubic hair. Differential diagnoses for atrophic vaginitis include various other conditions affecting the vulvovaginal area and urogenital function. Intravaginal estrogen therapy is the primary pharmacologic treatment, with options such as Conjugated estrogen cream, estradiol cream, estradiol tablet, estradiol vaginal ring, and estradiol transdermal patch. Low-dose local estrogen preparations are recommended to minimize systemic es trogen exposure. Risk factors for atrophic vaginitis include lack of vaginal births and smoking, which can worsen symptoms by reducing vaginal secretions due to vasoconstriction. If left untreated, atrophic vaginitis can lead to persistent itching, scarring from scratching, mucosal abrasions, and unresolved genitourinary complaints.

• The prevalence of atrophic vaginitis varies, with an estimated 10% to 50% of postmenopausal women and 15% of premenopausal women experiencing symptoms of genitourinary syndrome.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: